US 12,226,379 B2
Highly sustainable compositions for modulation of gene expression in human skin, and methods of production thereof
Deepak Dugar, Berkeley, CA (US)
Assigned to VISOLIS, INC., Dover, DE (US)
Filed by Visolis Technologies, Inc., Dover, DE (US)
Filed on Feb. 8, 2023, as Appl. No. 18/107,060.
Claims priority of provisional application 63/307,997, filed on Feb. 8, 2022.
Prior Publication US 2023/0248677 A1, Aug. 10, 2023
Int. Cl. A61K 31/191 (2006.01); A61K 8/365 (2006.01); A61K 9/00 (2006.01); A61K 9/06 (2006.01); A61Q 19/00 (2006.01); C12P 7/56 (2006.01)
CPC A61K 31/191 (2013.01) [A61K 8/365 (2013.01); A61K 9/0014 (2013.01); A61K 9/06 (2013.01); A61Q 19/00 (2013.01); C12P 7/56 (2013.01)] 43 Claims
 
1. A gene modulation formulation comprising mevalonolactone for modulating expression of one or more genes selected from group consisting of: COL1A1, COL1A2, COL4A1, ELN, EMILIN1, EMILIN2, MFAP5, FN1, LAMA1, TIMP1, TIMP2, TIMP3, TIMP4, HAS1, HAS2, HAS3, HABP4, HAPLN1, EGF, FGF7, HBEGF, KRT1, KRT2, KRT4, DEFA1, MMP1, MMP2, MMP3, MMP7, MMP9, NFATC1, IL1A, IL1B, TNFA, SELE, SELL, EDN1, EDN2, EDN3, PTGS2 (COX2), and POMC by at least 10 percent within 24 hours in epithelial tissue; wherein said mevalonolactone:
(a) is at least 97.5 percent pure in an aqueous solution as measured by HPLC,
(b) comprises less than 1 weight percent of fermentation byproducts, ethyl acetate, dichloromethane, tetrahydrofuran, isopropanol, petrochemicals, or combinations thereof, based on the total weight of said mevalonolactone, and
(c) comprises less than 10,000 ppm of odor-causing bodies as measured by gas chromatography (GC),
wherein said gene modulation formulation comprises 0.05 to 10 weight percent of said mevalonolactone.